ImmunoCellular Therapeutics Expands Phase 2 Trial For Brain Cancer Treatment

ImmunoCellular Therapeutics has expanded the number of sites for its phase two clinical trial ofa potential vaccine treatment for brain cancer.

Read more »

Navigating the Perilous Road: A Special Panel On Regulatory and Reimbursement Issues

A panel at OneMedForum NY 2011 will explore strategic planning considerations in the process of getting approval and reimbursement.

Read more »

June 23-24 OneMedForum New York

OneMedPlace Trans-Atlantic Conference on June 23rd-24th is a gathering of fast growing, emerging healthcare and life science companies in Europe […]

Read more »

Rib-X Pharmaceuticals’ Nobel Prize Winning Platform Combats Serious Infections

The antibiotic market is expected to reach $45 billion by 2012 driven by the deficiencies of currently available antibiotics.

Read more »

Small Bone Innovations Addresses Unmet Needs in Joint Replacement

Orthopedic companies have focused on developing devices for large bone trauma, leaving the small bone and joint field lacking.

Read more »

Read more »

OXiGENE Releases Promising Phase Two Data For Lung Cancer Drug

OXiGENE shares rose in pre-market trading Monday

Read more »

Emergent BioSolutions Acquires Rights To Lymphoma Drug

Emergent BioSolutions has acquired the rights to Zanolimumab, an investigational and late-stage antibody cancer therapy.

Read more »

June 22-23 2011 Wells Fargo Securities Healthcare Conference

Description: Explore the trends driving business in the Biotechnology, Health Care Facilities, Managed Care, Medical, Technology/Devices, Pharma Services, and Pharmaceuticals […]

Read more »

Hepregen Awarded $500,000 Massachusetts Life Sciences Center Grant

Hepregen, a leading provider of bioengineered solutions that increase success in drug development, was awarded a $500,000 grant as part of the Small Business Matching Grants program

Read more »